WG108

WG108 is an investigational stem cell-based cell therapy currently in the preclinical stage of development by Shenzhen Wingor Biotechnology. It is part of the company's 'WG' series of stem cell products (WG101-WG108), which are being explored for their potential in treating a broad range of conditions, including immune-mediated diseases, chronic illnesses, degenerative disorders, and cancers. As a stem cell therapy, WG108 is designed to leverage the regenerative and immunomodulatory properties of stem cells, although its specific cellular source and molecular targets have not been publicly disclosed by the developer. While other candidates in the pipeline, such as WG101, have advanced to Phase I/IIa clinical trials, WG108 remains in early-stage research.